MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
222.90
+57.20
+34.52%
After Hours: 223.04 +0.14 +0.06% 18:31 06/24 EDT
OPEN
219.37
PREV CLOSE
165.70
HIGH
231.64
LOW
209.23
VOLUME
9.19M
TURNOVER
0
52 WEEK HIGH
231.64
52 WEEK LOW
141.98
MARKET CAP
28.20B
P/E (TTM)
-82.2691
1D
5D
1M
3M
1Y
5Y
Alnylam Pharma (ALNY) Receives a Buy from TD Cowen
TipRanks · 22m ago
Notable Monday Option Activity: NFLX, ALNY, CMG
NASDAQ · 3h ago
Alnylam Pharmaceuticals Is Maintained at Buy by Needham
Dow Jones · 3h ago
Alnylam Pharmaceuticals Price Target Raised to $275.00/Share From $200.00 by Needham
Dow Jones · 3h ago
Needham Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $275
Benzinga · 4h ago
BUZZ-U.S. STOCKS ON THE MOVE-Arrowhead Pharmaceuticals, Nvidia, Alimera Sciences
The blue-chip Dow hit a one-month high in a broad-based rally on Monday. The Dow Jones Industrial Average was up 0.65% at 39,405.62. The top three S&P 500 percentage gainers: Ault Disruptive Technologies, Alimera Sciences. Nvidia, Arrowhead Pharmaceuticals, and Nvidia are among the day's losers.
Reuters · 4h ago
Strong Clinical Results Propel Alnylam Pharma’s Buy Rating and Price Target Increase
TipRanks · 4h ago
BUZZ-Alnylam jumps as heart disease drug succeeds in key study
Alnylam Pharmaceuticals shares surge as much as 40% to highest level since Feb 2023. Company says its heart disease drug vutrisiran succeeds in key study. Drug helped reduce deaths and heart-related hospitalizations by 33% in patients with rare heart disease. Set to add over $8 bln in market cap.
Reuters · 4h ago
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.